Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind Corporation shares traded lower Wednesday following its licensing and collaboration agreement for an inhaled, rapid-acting GLP-1 program. The article provides no financial terms, development timeline, or clinical data, but the negative share reaction indicates investor caution around the deal's implications.